.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: RE29892

« Back to Dashboard

Claims for Patent: RE29892

Title: Composition and method of treating dopamine deficiency in brain tissue
Abstract:The dopamine content in brain tissue of animals is increased by administering to the animal L-dopa or its salts in combination with L-.alpha.-hydrazino-.alpha.-lower alkyl-3,4-dihydroxyphenyl propionic acid or its salts .[.or .alpha.-hydrazino-3,4-dihydroxyphenyl propionic acid or its salts.].. The increased dopamine content in brain tissue tends to alleviate some of the symptoms caused by Parkinsonism and similar diseases.
Inventor(s): Bayne; Gilbert M. (Lansdale, PA)
Assignee: Merck & Co. Inc. (Rahway, NJ)
Application Number:05/790,155
Patent Claims: 1. A method of increasing the dopamine content in the brain tissue of an animal which comprises administering to the animal an effective amount of a composition containing a Compound (A) selected from the group consisting of L-dopa and a pharmaceutically acceptable non-toxic salt thereof and a Compound (B) selected from the group consisting of .Iadd.L.Iaddend.-.alpha.-hydrazino-.alpha.-lower alkyl-3,4-dihydroxyphenyl propionic acid .[.and .alpha.-hydrazino-3,4-dihydroxyphenyl propionic acid.]. and a pharmaceutically acceptable non-toxic salt thereof, wherein the ratio of Compound (A) to Compound (B) is from about 0.05 to about 500.

2. The method of claim 1 wherein the Compound (B) is L-.alpha.-hydrazino-.alpha.-methyl-3,4-dihydroxyphenyl propionic acid. .[.3. The method of claim 1 wherein the Compound (B) is

.alpha.-hydrazino-3,4-dihydroxyphenyl propionic acid..]. 4. A method of increasing the dopamine content in the bran tissue of an animal which comprises administering to the animal from about 0.05 to about 300 mg./kg. of body weight of a composition containing a Compound (A) selected from the group consisting of L-dopa and a pharmaceutically acceptable non-toxic salt thereof and a Compound (B) selected from the group consisting of L-.alpha.-hydrazino-.alpha.-lower alkyl-3,4-dihydroxyphenyl propionic acid .[.and .alpha.-hydrazino-3,4-dihydroxyphenyl propionic acid.]. and a pharmaceutically acceptable non-toxic salt thereof, wherein the ratio of

Compound (A) to Compound (B) is from about 0.05 to about 500. 5. The method of claim 4 wherein the Compound (B) is L-.alpha.-hydrazino-.alpha.-methyl-3,4-dihydroxyphenyl propionic acid. .[.6. The method of claim 4 wherein the Compound (B) is

.alpha.-hydrazino-3,4-dihydroxyphenyl propionic acid..]. 7. The method of

claim 4 wherein the compounds are administered orally. 8. The method of

claim 4 wherein the compounds are administered sequentially. 9. The method

of claim 4 wherein the compounds are administered simultaneously. 10. The method of claim 4 wherein the ratio of Compound (A) to Compound (B) is

from about 0.5 to about 50. 11. The method of claim 4 wherein the ratio of

Compound (A) to Compound (B) is from about 1 to about 30. 12. A pharmaceutical composition comprising a Compound (A) selected from the group consisting of L-dopa and a pharmaceutically acceptable non-toxic salt thereof and a Compound (B) selected from the group consisting of L-.alpha.-hydrazino-.alpha.-lower alkyl-3,4-dihydroxyphenyl propionic acid .[.and .alpha.-hydrazino-3,4-dihydroxyphenyl propionic acid.]. and a pharmaceutically acceptable non-toxic salt thereof, wherein the ratio of

Compound (A) to Compound (B) is from about 0.05 to about 500. 13. The pharmaceutical composition of claim 12 wherein the ratio of Compound (A)

to Compound (B) is from about 0.5 to about 50. 14. The pharmaceutical composition of claim 12 wherein the ratio of Compound (A) to Compound (B) is from about 1 to about 30. .Iadd. 15. The pharmaceutical composition of claim 12 wherein the Compound (B) is L-.alpha.-hydrazino-.alpha.-methyl-3,4-dihydroxyphenyl propionic acid..Iaddend.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc